Olopatadine — $0 with Membership
Olopatadine has an active canonical formulary match. No-additional-cost pricing is subject to its listed supply, quantity, fill, and fulfillment limits.
Olopatadine Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 with membership |
| Typical Retail | $41.00 |
Free with membership subject to the listed formulary limits.
About Olopatadine
Olopatadine is a prescription medication. Ask your doctor if Olopatadine is right for you.
Other strengths and forms of Olopatadine
Conditions Treated with Olopatadine
How to Check Olopatadine Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Olopatadine at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Allergic Conjunctivitis
Other medications in Eye & Vision
What Olopatadine is approved for (FDA label)
Olopatadine hydrochloride nasal spray is indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 years of age and older. Olopatadine hydrochloride nasal spray is an H 1 receptor antagonist indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 6 years of age and older ( 1 ).
Source: Read the full FDA label on DailyMed. Label effective date: August 15, 2024.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Olopatadine (FDA label)
Nasal spray: 665 mcg olopatadine hydrochloride per spray supplied in a white plastic bottle with a metered-dose manual spray pump, a white nasal applicator, a blue overcap and a blue clip. Nasal spray: 665 mcg of olopatadine hydrochloride in each spray ( 3 ).
Source: FDA prescribing information (DailyMed). Set ID: db024b9c-681f-4503-9fda-1eaa1add4746. SPL document ID: 1f877375-4665-4f9b-92af-93c6d73e2313. Label effective date: August 15, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Olopatadine (FDA label)
The most clinically significant adverse reactions described in other sections of labeling include: • Epistaxis, Nasal Ulceration, and Nasal Septal Perforation [ see Warnings and Precautions ( 5.1 ) ] • Somnolence and Impaired Mental Alertness [ see Warnings and Precautions ( 5.2 ) ] The most common (>1%) adverse reactions, included bitter taste, headache, epistaxis, pharyngolaryngeal pain, post-nasal drip, cough, and urinary tract infection in patients 12 years of age and older and epistaxis, headache, upper respiratory tract infection, bitter taste, pyrexia, and rash in patients 6 to 11 years of age ( 6.1 ).
Source: FDA prescribing information (DailyMed). Set ID: db024b9c-681f-4503-9fda-1eaa1add4746. SPL document ID: 1f877375-4665-4f9b-92af-93c6d73e2313. Label effective date: August 15, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Olopatadine (FDA label)
None. None ( 4 ).
Source: FDA prescribing information (DailyMed). Set ID: db024b9c-681f-4503-9fda-1eaa1add4746. SPL document ID: 1f877375-4665-4f9b-92af-93c6d73e2313. Label effective date: August 15, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Olopatadine (FDA label)
• Epistaxis, Nasal Ulceration, and Nasal Septal Perforation : Monitor patients periodically for signs of adverse effects on the nasal mucosa. Discontinue if ulcerations or perforations occur. Avoid use in patients with nasal disease other than allergic rhinitis ( 5.1 ). • Avoid engaging in hazardous occupations requiring complete mental alertness and coordination, such as driving or operating machinery when taking olopatadine hydrochloride nasal spray ( 5.2 ). • Avoid concurrent use of alcohol or other central nervous system depressants with olopatadine hydrochloride nasal spray ( 5.2 ). 5.1 Local Nasal Effects Epistaxis and Nasal Ulceration In placebo-controlled clinical trials (vehicle nasal spray) of 2 weeks to 12 months duration, epistaxis and nasal ulcerations were reported [ see Adverse Reactions ( 6.1 ) ]. Nasal Septal Perforation Three placebo-controlled long term (12 months) safety trials (vehicle nasal spray) were conducted.
Source: FDA prescribing information (DailyMed). Set ID: db024b9c-681f-4503-9fda-1eaa1add4746. SPL document ID: 1f877375-4665-4f9b-92af-93c6d73e2313. Label effective date: August 15, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Olopatadine (FDA label)
Formal drug-drug interaction studies were not conducted for olopatadine hydrochloride nasal spray. Drug interactions with inhibitors of liver enzymes are not anticipated because olopatadine is eliminated predominantly by renal excretion. Drug interactions involving P450 inhibition and plasma protein binding are also not expected [ See Clinical Pharmacology ( 12.3 ) ].
Source: FDA prescribing information (DailyMed). Set ID: db024b9c-681f-4503-9fda-1eaa1add4746. SPL document ID: 1f877375-4665-4f9b-92af-93c6d73e2313. Label effective date: August 15, 2024. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.